44,668 Shares in Genmab A/S Sponsored ADR $GMAB Acquired by Y Intercept Hong Kong Ltd

Posted by Francis Steltz on Jul 12th, 2026

Y Intercept Hong Kong Ltd purchased a new stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) in the first quarter, Holdings Channel.com reports. The institutional investor purchased 44,668 shares of the company’s stock, valued at approximately $1,198,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. Paradigm Biocapital Advisors LP acquired a new stake in Genmab A/S during the third quarter worth approximately $117,063,000. Orbis Allan Gray Ltd grew its position in shares of Genmab A/S by 30.2% in the 4th quarter. Orbis Allan Gray Ltd now owns 14,418,462 shares of the company’s stock valued at $444,089,000 after buying an additional 3,340,456 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in Genmab A/S by 36.6% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock worth $153,324,000 after acquiring an additional 1,334,919 shares in the last quarter. Pictet Asset Management Holding SA acquired a new stake in Genmab A/S during the 4th quarter worth $33,835,000. Finally, Perpetual Ltd purchased a new stake in Genmab A/S in the fourth quarter valued at $25,478,000. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Stock Performance

Genmab A/S stock traded down $0.78 during midday trading on Friday, hitting $29.00. 4,927,154 shares of the company’s stock were exchanged, compared to its average volume of 1,608,152. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.17 and a current ratio of 2.18. The stock has a market cap of $18.08 billion, a price-to-earnings ratio of 21.97, a price-to-earnings-growth ratio of 1.87 and a beta of 0.84. Genmab A/S Sponsored ADR has a 12-month low of $21.00 and a 12-month high of $35.43. The firm’s 50 day simple moving average is $26.44 and its 200 day simple moving average is $28.58.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Truist Financial began coverage on Genmab A/S in a report on Wednesday, May 27th. They set a “buy” rating and a $40.00 price objective on the stock. BNP Paribas Exane raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd. HC Wainwright upped their target price on Genmab A/S from $38.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, July 2nd. The Goldman Sachs Group upgraded Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 22nd. Finally, Wolfe Research began coverage on Genmab A/S in a research report on Friday, March 27th. They set an “outperform” rating and a $32.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $38.21.

Get Our Latest Research Report on Genmab A/S

Genmab A/S Company Profile

(Free Report)

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.